Additional bipolar indication for Seroquel

Seroquel and Seroquel XL (quetiapine) have been approved for the treatment of major depressive episodes in adults with bipolar disorder, in addition to the products' existing indications for schizophrenia and manic episodes. The new indication, for which the maximum daily dose is 600mg, carries a black triangle to indicate that all adverse events should
be reported.

View Seroquel drug record

Further information: AstraZeneca

To sign up for the MIMS monthly news update, register at

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more